Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
About Altimmune, Inc.
Altimmune, Inc. (NASDAQ: ALT) is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapeutics and vaccines that address significant public health challenges. With a focus on obesity, non-alcoholic steatohepatitis (NASH), chronic hepatitis B, and cancer, Altimmune leverages proprietary technologies to develop next-generation peptide-based treatments and immunotherapies.
Core Technologies
Altimmune's development pipeline is built on two complementary platform technologies:
- Densigen™ T-cell Platform: This platform is designed to direct the immune system against traditionally challenging disease targets, such as chronic infections and cancer, by targeting multiple antigens simultaneously. This approach enhances immune response precision and efficacy.
- RespirVec™ Intranasal Delivery Platform: Utilizing a needle-free delivery system, this platform enables rapid and broad immunity against pathogens. Its ease of manufacturing and stability make it a promising alternative to conventional vaccines.
Product Pipeline
Altimmune's pipeline includes advanced candidates targeting metabolic diseases and infectious diseases:
- Pemvidutide: A peptide-based GLP-1/glucagon dual receptor agonist in development for obesity and NASH. Pemvidutide mimics the synergistic effects of diet and exercise, suppressing appetite and enhancing energy expenditure while reducing liver fat and cardiovascular risk factors.
- HepTcell: A therapeutic vaccine designed to stimulate an immune response in individuals with chronic hepatitis B, aiming to achieve functional cure rates.
Market Position and Opportunities
Operating within the competitive biotechnology sector, Altimmune addresses critical unmet medical needs in obesity and liver diseases, which represent multi-billion-dollar global markets. The company's innovative platforms and clinical assets position it to differentiate from competitors by offering unique mechanisms of action, such as dual receptor agonism and multi-antigen immune targeting.
Challenges and Strategic Focus
As a clinical-stage company, Altimmune faces challenges typical of the biotechnology industry, including regulatory hurdles, clinical trial complexities, and manufacturing scalability. However, its robust technological foundation and focus on high-impact therapeutic areas provide a strategic advantage. The company's ability to secure regulatory designations, such as the FDA Fast Track for pemvidutide, underscores its potential to address pressing health concerns efficiently.
Conclusion
Altimmune, Inc. stands out as a dynamic player in the biopharmaceutical industry, combining cutting-edge platforms with a commitment to addressing significant public health challenges. Through its innovative pipeline and strategic focus, the company is well-positioned to make meaningful contributions to the treatment of metabolic and infectious diseases.
Altimmune has initiated a Phase 2 clinical trial for HepTcell, an innovative immunotherapeutic designed to treat chronic hepatitis B (CHB). Conducted across the U.S., Canada, and Europe, this double-blind study includes 80 adults and will assess safety and efficacy over 24 weeks, with a focus on virological response. CHB affects 292 million globally, with no current cure, leading to significant health risks. HepTcell aims to restore T cell function, addressing a critical unmet need in CHB therapy.
Altimmune, Inc. (Nasdaq: ALT) announced a clinical hold by the FDA on its IND application for AdCOVID, an intranasal COVID-19 vaccine. The FDA has requested protocol modifications and additional CMC data. Altimmune has addressed these requests and does not foresee a significant delay in its clinical development timeline. The company is preparing to initiate a Phase 1 clinical trial for AdCOVID, which has demonstrated promising preclinical results showing robust immune responses against COVID-19.
Altimmune, Inc. (Nasdaq: ALT) announced that Dr. Scott Harris, their Chief Medical Officer, will present on ALT-801, a promising GLP-1/glucagon dual receptor agonist aimed at treating non-alcoholic steatohepatitis (NASH). This presentation is part of the 4th Annual NASH Summit 2020 Digital Conference, taking place from December 15-18, 2020. Dr. Harris will also join a panel discussion on NASH treatments on December 16. ALT-801 shows potential in addressing obesity linked to NASH, with Phase 1 data expected in Q2 2021.
Altimmune, Inc. has initiated dosing in a Phase 1 clinical trial for ALT-801, a dual GLP-1/glucagon receptor agonist targeting non-alcoholic steatohepatitis (NASH), affecting over 13 million adults in the U.S. The trial in Australia will evaluate safety, pharmacokinetics, and activity in 50-60 volunteers. Initial results, including weight loss and liver fat reduction, are expected in Q2 2021, with a follow-up Phase 1b study planned for Q3 2021. The drug aims to improve tolerability and efficacy in treating NASH compared to existing therapies.
Altimmune has submitted an Investigational New Drug (IND) application for its single-dose intranasal COVID-19 vaccine, AdCOVID, to the FDA. AdCOVID aims to stimulate comprehensive immunity, including local nasal mucosal immunity, crucial for preventing virus transmission. The Phase 1 trial is expected to begin in Q4 2020, with data readout anticipated in Q1 2021. The vaccine's advantages include easy administration, room-temperature transport, and potential pediatric use. The FDA has approved the study design and patient population, deeming no additional toxicology studies necessary.
Altimmune, Inc. (Nasdaq: ALT) announced its participation in upcoming virtual investor conferences. These events include the Jefferies London Virtual Healthcare Conference on November 17, 2020, the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 23 to December 3, 2020, and the 3rd Annual Evercore ISI Virtual HealthCONx Conference on December 2, 2020. All sessions will be accessible through the investor relations section of Altimmune's website. The company focuses on developing intranasal vaccines and therapies for diseases, including COVID-19 and liver disease.
Altimmune has announced an agreement with Lonza to manufacture its AdCOVID intranasal vaccine for COVID-19. This partnership aims to enhance Altimmune's commercial readiness for potential vaccine distribution in 2021. The AdCOVID vaccine is designed for easy administration and aims to provide broad immune responses, including mucosal immunity. Preclinical studies indicate a significant increase in mucosal IgA. The company plans to initiate a Phase 1 clinical trial in Q4 2020, with results expected in Q1 2021.
Altimmune, Inc. (Nasdaq: ALT) reported its Q3 2020 financial results, highlighting a revenue increase to $2.9 million from $0.6 million year-over-year, largely driven by U.S. government contracts. The company is advancing several investigational candidates, including AdCOVID, T-COVID, and ALT-801, with plans for clinical trials commencing this year. Research and development expenses rose to $17 million, leading to a net loss of $17.8 million, or $0.54 per share. Altimmune has secured approximately $200 million to support its pipeline initiatives.
Altimmune, Inc. (Nasdaq: ALT) announced it will release its third quarter 2020 financial results on November 10, 2020. A conference call for investors will follow at 8:30 a.m. ET on the same day, where management will discuss the financial results and provide a business update. The company, focused on developing intranasal vaccines and therapies, has a diverse pipeline including products for COVID-19, anthrax, and liver disease. For more details, investors can access the conference call via a webcast.
Altimmune, a clinical-stage biopharmaceutical company (Nasdaq: ALT), announced its participation in two upcoming virtual investor conferences. The first is the H.C. Wainwright Hepatitis B Virus Conference on October 20, 2020, at 1:30 PM EDT, which will be webcast through the company's investor relations page. The second event is the B. Riley Securities Liver Disease Symposium on October 29, 2020. Altimmune specializes in intranasal vaccines and therapies for liver diseases, including COVID-19 and hepatitis B.
FAQ
What is the current stock price of Altimmune (ALT)?
What is the market cap of Altimmune (ALT)?
What does Altimmune, Inc. specialize in?
What are Altimmune's core technologies?
What is pemvidutide?
What makes Altimmune's approach unique?
What challenges does Altimmune face?
What markets does Altimmune target?
How does Altimmune generate revenue?
Who are Altimmune's competitors?
What is the significance of the FDA Fast Track designation for pemvidutide?
What is the role of the Densigen™ T-cell platform?
